hypothesized that Alzheimer’s is caused by an amyloid beta (Aβ) protein known as Aβ*56. Aβ proteins have long been thought to contribute to Alzheimer’s. Ashe’s study asserted that “Aβ ...

This mechanism, which involves extracellular accumulation of a 56 kDa soluble amyloid-β (Aβ) assembly, dubbed Aβ*56, has been shown to induce memory deficit in middle-aged Tg2576 MICE ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the ...

The test, known as AD-Detect Abeta 42/40 and p-tau217 Evaluation, is said to combine amyloid beta (AB) 42/40 blood level outcomes, which are determined by Quest’s tandem mass spectrometry techniques ...

Panelists discuss how managing patients with mild cognitive impairment using amyloid-targeting therapies faces significant barriers including limited healthcare infrastructure for complex diagnostic ...

Although there are many outstanding questions about Alzheimer’s and a significant lack of effective drugs, scientists believe a protein called amyloid-beta plays an important role in the condition.

We examined acetylcholinesterase, plasma neuronal proteins, secreted beta-amyloid precursor protein (APP), and amyloid-beta 40 and amyloid-beta 42 peptides in children with and without autism.

March 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta ...

Background High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary endpoints. Neither drug ...

Biologically speaking, Alzheimer’s is characterized by the progression of amyloid-beta plaques and tau-positive neurofibrillary tangles, the latter of which are closely associated with loss of neurons ...

Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C., April 2, 2025 /PRNewswire ...